Search tips
Search criteria 


Logo of thoraxThoraxVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Thorax. 2007 November; 62(11): 1018.
PMCID: PMC2117115


The patient was submitted to lung and prostate biopsies which showed pulmonary alveolar proteinosis (PAP) and embryonal rhabdomyosarcoma (fig 1A and BB).). A radical cystoprostatectomy with an ileal conduit was performed without curative intention due to lymph node metastasis and 1 month later the patient underwent pelvic radiotherapy and doxorubicin‐based chemotherapy. The patient refused treatment of the pulmonary disease. There was progression of the lymph node metastasis and no improvement in the pulmonary symptoms or radiological findings after treatment. The patient died 1 year after surgery as a result of intra‐abdominal spread of the neoplasm.

figure tx83717a.f1
Figure 1 (A) Alveolar proteinosis (H&E stain, magnification 100×). (B) Embryonal rhabdomyosarcoma of prostate with myogenin positivity (immunohistochemical stain, magnification 400×).

PAP is a rare cause of respiratory failure which results from accumulation of lipoproteinaceous material in the alveolar space. It is believed to be caused by dysfunction of the clearance of surfactant from the alveoli by macrophages.1 PAP is associated with high levels of autoantibodies against granulocyte‐macrophage colony stimulating factor (GM‐CSF) in the blood and tissues. Neutralisation of the biological activity of GM‐CSF may cause neutrophil and alveolar macrophage dysfunction, which would explain the pathogenesis of PAP.2 It may be secondary to many conditions such as acute silicosis and other inhalation syndromes, immunodeficiency disorders, infections, haematological malignancies (predominantly myelogenous leukaemias), metastatic melanoma to lung and breast cancer, but no association with prostate cancer is known.1,2,3,4 These associated diseases and GM‐CSF neutralisation suggest that PAP is characterised by defective immune function.2

Embryonal rhabdomyosarcoma of the prostate occurs predominantly in male infants and children and is a rare and highly malignant tumour. Fewer than 20 cases of prostate rhabdomyosarcoma have been reported in adults.5 In the present case there was a temporal association between the urinary and pulmonary symptoms. The PAP may have been a secondary manifestation of the prostate tumour, but its treatment did not improve the pulmonary symptoms or the radiological findings.

From the question on page 1002


1. Venkateshiah S B, Thomassen M J, Kavuru M S. Pulmonary alveolar proteinosis. Clinical manifestations and optimal treatment strategies. Treat Respir Med 2004. 3217–227.227 [PubMed]
2. Uchida K, Beck D C, Yamamoto T. et al GM‐CSF autoantibodies and neutrophil dysfunction in pulmonary alveolar proteinosis. N Engl J Med 2007. 356567–579.579 [PubMed]
3. Goldstein L S, Kavuru M S, Curtis‐McCarthy P. et al Pulmonary alveolar proteinosis. Clinical features and outcomes. Chest 1998. 1141357–1362.1362 [PubMed]
4. Schiller V, Aberle D R, Aberle A M. Pulmonary alveolar proteinosis. Occurrence with metastatic melanoma to lung. Chest 1989. 95466–467.467 [PubMed]
5. Sexton W J, Lance R E, Reyes A O. et al Adult prostate sarcoma: the M D Anderson Cancer Center experience. J Urol 2001. 166521–525.525 [PubMed]

Articles from Thorax are provided here courtesy of BMJ Publishing Group